References
- Wang B, Wang J, Huang SQ, et al. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab 2009;10:781–834
- Gray IC, Nobile C, Muresu R, et al. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 1995;28:328–32
- Booven DV, Marsh S, McLeod H, et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 2010;20:277–81
- Mo SL, Zhou ZW, Yang LP, et al. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Curr Drug Metab 2009;10:1075–126
- Tracy TS, Marra C, Wrighton SA, et al. Studies of flurbiprofen 4′-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 1996;52:1305–9
- Hiratsuka M. In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Pharmacokinet 2012;27:68–84
- Dai DP, Xu RA, Hu LM. CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. Pharmacogenomics J 2013;14:1–8
- Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 2002;12:251–63
- Tracy TS, Hutzler JM, Haining RL, et al. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 2002;30:385–90
- Si D, Guo Y, Zhang Y, et al. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004;14:465–9
- Guo Y, Wang Y, Si D, et al. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 2005;35:853–61
- Blaisdell J, Jorge-Nebert LF, Coulter S, et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004;14:527–37
- Liu Y, Jeong H, Takahashi H, et al. Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther 2012;91:660–5
- Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 2005;15:779–86
- Zhao F, Loke C, Rankin SC, et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance wayfaring dose. Clin Pharmacol Ther 2004;76:210–19
- DeLozier TC, Lee SC, Coulter SJ, et al. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 2005;315:1085–90
- Veenstra DL, Blough DK, Higashi MK, et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005;77:353–64
- Maekawa K, Fukushima-Uesaka H, Tohkin M, et al. Four novel defective alleles and comprehensive Haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 2006;16:497–514
- Matimba A, Del FJ, Van BC, Masimirembwa C. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 2009;3:169–90
- Yin T, Maekawa K, Kamide K, et al. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008;31:1549–57